EMBX Embrex

RESEARCH TRIANGLE PARK, N.C., Oct. 3 /PRNewswire-FirstCall/ -- Embrex, Inc., The In Ovo Company, (NASDAQ:EMBX) today announced David Shapiro, DVM, Dipl. ACPV, was appointed Senior Director, Global Veterinary Services. Effective immediately, he reports to Brian Hrudka, Vice President, Global Marketing. Dr. Shapiro received his veterinary degree from Purdue University, where he studied avian pathology under Dr. Roland Winterfield. He began his poultry health career with Salsbury Laboratories as a technical services veterinarian. During his subsequent 24 years in the poultry industry, he has held technical and management positions with several important allied industry companies including Hy-Line International, and Hoechst Roussel Vet. He was also staff veterinarian for California broiler integrator, Zacky Farms. "We are pleased that Dr. Shapiro joined Embrex. Since 1999, he has been an independent poultry health consultant to a broad range of broiler integrators, egg producers, breeders, poultry health companies and biotech concerns worldwide. In summary, virtually all of his veterinary activities have involved working for Embrex customers, potential customers, or the companies which supply them," said Hrudka. "We believe his skills and experiences will raise the poultry health capabilities of Embrex to a new level, especially as he works with our team to help ensure the successful USDA registration, marketing and service activities surrounding Inovocox(TM), Embrex's in ovo coccidiosis vaccine." Coccidiosis is a parasitic disease of the bird's digestive system. While not always fatal, it causes gastrointestinal distress to poultry, interferes with weight gain and a bird's overall health. Currently, approximately $350 million is spent annually worldwide to prevent this parasitic disease. About Embrex Celebrating its 20th anniversary, Embrex, Inc., The In Ovo Company(R), headquartered in Research Triangle Park, NC, is an international biotechnology company engaged in the development of innovative in ovo (in the egg) solutions that meet the needs of today's global poultry industry. The company's unique integration of several scientific and engineering disciplines enables it to be the leading provider of in ovo, value-added solutions with its automated injection and detection devices as well as its select vaccines. For additional information, visit the company web site at http://www.embrex.com/. This release contains forward-looking statements, including statements with respect to future financial results, products, services, and markets. These statements involve risks and uncertainties that could cause actual results to differ materially. Risks include without limitation the degree of growth in the poultry industry in the United States and globally, competition arising in the United States and elsewhere, possible decreases in production by our customers, avian disease outbreaks in Embrex's markets, market acceptance and cost of expansion in new geographic markets and with new products, including the Company's ability to penetrate new markets and the degree of market acceptance of new products, the ability of Embrex's contract manufacturers to support our products, the complete commercial development of potential future products on a cost effective basis, including Inovocox(TM), and the ability to obtain regulatory approval of products. Such approval is dependent upon a number of factors, such as results of trials, the discretion of regulatory officials, and potential changes in regulations. Additional information on these risks and other factors, which could affect the Company's financial results, is included in the Company's Forms 10-K, 10-Q and other filings with the Securities and Exchange Commission. Embrex(R), Bursaplex(R), Newplex(TM), Inovoject(R), Inovocox(TM), Egg Remover(R), Vaccine Saver(R), and The In Ovo Company(R) are trademarks of Embrex, Inc. CONTACT: Ellen Corliss Moore Vice President, Investor Relations & Corporate Communications (919) 314-2561 DATASOURCE: Embrex, Inc. CONTACT: Ellen Corliss Moore, Vice President, Investor Relations & Corporate Communications of Embrex, Inc., +1-919-314-2561 Web site: http://www.embrex.com/

Copyright